Introduction {#S1}
============

Perinatal brain injury due to HI is a serious health problem affecting full-term and preterm human neonate and is a contributor to perinatal morbidity and mortality ([@B51]). Effective pharmacological treatments are urgently required to prevent the brain damage and poor long-term outcome.

The Shh signaling pathway serves as a key component in embryonic development and adult stem cell function. After secretion, Shh binds to its receptor Ptch1, which suppresses the Smo receptor. Subsequently, this allows Gli-1/2 to enter the nucleus and initiating the expressions of target genes ([@B10]). A number of beneficial effects result from Shh signaling as demonstrated in various pathological states of brain and spinal cord pathology, including acute brain injury ([@B3]), Alzheimer's disease ([@B50]), Parkinson's disease ([@B49]), stroke ([@B57]), multiple sclerosis and demyelination ([@B18]), spinal cord injury ([@B8]), and HIV-associated neurological disorders ([@B44]). Complementing these findings are results from reports indicating that activation of the Shh signaling pathway has beneficial effects against brain injury. For example, reductions in spinal cord injury have been reported following the application of recombinant Shh protein or the intravenous hedgehog agonist, Ag11.1 in adult rats ([@B7], [@B8]). In addition, exogenous Shh protein administration exerts angiogenic effects and protects against brain injury from ischemia ([@B13]).

Purmorphamine is a purine-derivative, small molecule SMO receptor agonist ([@B45]). In 2002, Schultz et al. demonstrated that PUR induced osteoblast differentiation of multipotent mesenchymal progenitor cells and lineage-committed preosteoblasts ([@B54]). In addition, PUR enhanced cell survival in HT22 cells in response to an oxidative challenge ([@B35]). PUR has also been shown to promote barrier formation and plays a role in activation of the endogenous anti-inflammatory system within the central nervous system ([@B2]). Recently, PUR was found to protect cortical neurons and restore neurological deficits after ischemic stroke in rats ([@B12]). Work within our laboratory has revealed that PUR exerts neuroprotection against subarachnoid hemorrhage-induced injury in rats ([@B22]). To the best of our knowledge, the potential effects of PUR within neonatal animals subjected to HI injury remain unknown. In the present study, we examined the influences of a short-term PUR administration on acute brain injury and long-term neurobehavioral dysfunction in neonatal mice subjected to HI injury.

Materials and Methods {#S2}
=====================

HI Model and Treatment {#S2.SS1}
----------------------

The Rice-Vannucci model was used to generate HI injury ([@B28]). Male C57BL/6J mouse pups on PND 7 were randomly selected. The pups were anesthetized, and the right common carotid artery was isolated and permanently double-ligated. After surgery, the pups were allowed to recover for 1 h and then placed in a hypoxia chamber (humidified 8% O~2~ + 92% N~2~) for 90 min to induce HI injury. Sham controls consisted of anesthetized pups with exposed right carotid arteries.

The PND7 pups were randomized within litters and allocated to one of five groups: (1) Sham + saline (Sham, *n* = 45); (2) HI + saline (HI, *n* = 48); (3) HI + PUR (*n* = 47); (4) HI + PUR + Cyc (Shh antagonist) (*n* = 48); and (5) HI + Cyc (*n* = 48). The initial PUR (10 mg/kg, i.p.) or equal amounts of saline treatment were administered at 24 h after HI injury and followed by daily treatments for the subsequent 3 days. The HI + PUR + Cyc group were pretreated with Cyc (0.5 mg/kg) followed by PUR treatment 30 min later, while the HI + Cyc animals (group 5) were pretreated with Cyc, followed by saline treatment 30 min later. A summary of the experimental schedule is presented in [Supplementary Figure S1](#FS1){ref-type="supplementary-material"}, while all reagents used in this study are contained within [Table 1](#T1){ref-type="table"}.

###### 

All reagents used in this study.

  Primary antibodies                                                                                      Dilution                                                  Cat. No.         Producer
  ------------------------------------------------------------------------------------------------------- --------------------------------------------------------- ---------------- -------------------------------------------------------
  **1.1 Antibodies used for Western blot analysis**                                                                                                                                  
  Anti-β-actin                                                                                            1:1000                                                    TA-09            Zhongshan Golden Bridge Biotechnology, Beijing, China
  Anti-Bax                                                                                                1:1000                                                    50599-2-Ig       Proteintech Group, United States
  Anti-Bcl-2                                                                                              1:1000                                                    12789-1-AP       Proteintech Group, United States
  Anti-Cleaved caspase-3                                                                                  1:500                                                     Asp175, \#9661   Cell Signaling, Beverly, MA, United States
  Anti-Caspase-3                                                                                          1:1000                                                    19677-1-AP       Proteintech Group, United States
  Anti-Nrf2                                                                                               1:500                                                     16396-1-AP       Proteintech Group, United States
  Anti-Syn                                                                                                1:1000                                                    D35E4, \#5461    Cell Signaling, Beverly, MA, United States
  Anti-PSD95                                                                                              1:1000                                                    D74D3, \#3409    Cell Signaling, Beverly, MA, United States
  Anti-Shh                                                                                                1:1000                                                    20697-1-AP       Proteintech Group, United States
  Anti-Ptch                                                                                               1:500                                                     ab53715          Abcam, Cambridge, United Kingdom
  Anti-Gli-1                                                                                              1:500                                                     ab151796         Abcam, Cambridge, United Kingdom
  **1.2 Antibodies used for immunofluorescence and immunohistochemistry staining**                                                                                                   
  Anti-NeuN                                                                                               1:100                                                     ab104224         Abcam, Cambridge, United Kingdom
  Anti-Syn (mouse)                                                                                        1:100                                                     60191-1-Ig       Proteintech Group, United States
  Anti-PSD95 (rabbit)                                                                                     1:100                                                     20665-1-AP       Proteintech Group, United States
  Anti-Cleaved caspase-3                                                                                  1:100                                                     Asp175, \#9661   Cell Signaling, Beverly, MA, United States
  Anti-Iba-1                                                                                              1:100                                                     GTX632426        GeneTex, Inc.,Irvine, CA, United States
  **1.3 Other major reagents used in this study**                                                                                                                                    
  Purmorphamine                                                                                           Selleck Chemicals (Houston, TX, United States)                             
  Cyclopamine                                                                                             Selleck Chemicals (Houston, TX, United States)                             
  Radioimmunoprecipitation assay (RIPA)                                                                   Beyotime Institute of Biotechnology, Jiangsu, China                        
  Phenylmethane-sulfonyl fluoride (PMSF)                                                                  Beyotime Institute of Biotechnology, Jiangsu, China                        
  PhosSTOP phosphatase inhibitor                                                                          Roche Diagnostics Gmbh, Indianapolis, IN, United States                    
  BCA protein assay kit                                                                                   CWBIO, Haimen, Jiangsu, China                                              
  5 × loading buffer                                                                                      Beyotime Institute of Biotechnology, Jiangsu, China                        
  PVDF membranes                                                                                          Millipore, United States                                                   
  Enhanced chemiluminescence                                                                              Millipore, United States                                                   
  TRIzol reagent                                                                                          CWBIO, Haimen, Jiangsu, China                                              
  RevertAid First Strand cDNA Synthesis Kit                                                               Thermo scientific, Waltham, MA, United States                              
  GolView                                                                                                 Beijing Solarbio Science and Technology Co, China                          
  4,6-Diamidino-2-phenylindole (DAPI)                                                                     Beyotime Institute of Biotechnology, Jiangsu, China                        
  Dihydroethiduim                                                                                         Beyotime Institute of Biotechnology, Jiangsu, China                        
  Terminal deoxynucleotidyl transferase dUTP-mediated nick end labeling (TUNEL) Apoptosis Detection kit   KeyGen Bio Tech Co. (Nanjing, China).                                      
  Rhodamine (TRITC)-conjugated goat anti-rabbit IgG                                                       Proteintech Group, United States                                           
  Fluorescein (FITC)-conjugated affinipure goat anti-mouse IgG                                            Proteintech Group, United States                                           
  Peroxidase-conjugated goat anti-rabbit/mouse IgG                                                        Zhongshan Golden Bridge Biotechnology                                      
  2,3,5-Triphenyltetrazolium chloride monohydrate (TTC)                                                   Sigma--Aldrich, St. Louis, MO, United States                               
  Cresyl violet acetate                                                                                   Sigma--Aldrich, St. Louis, MO, United States                               
  APC anti-mouse CD45                                                                                     Biolegend (103112)                                                         
  FITC anti-mouse/human CD11b                                                                             Biolegend (101206)                                                         

The animal experiments were performed based on the International Guiding Principles for Animal Research provided by the Council for International Organizations of Medical Sciences (CIOMS), and procedures were approved by the Animal Ethical and Welfare Committee of Shandong University. Participants who worked with the animal models were trained according to Institutional Animal Care and Use Committee Guidebook (IACUC) rules.

Behavioral Testing {#S2.SS2}
------------------

Hypoxic-ischemic insult led to hyperactivity at PND21, but no differences was found in spontaneous or in open-field activity at PND 90 ([@B30]). Rats at PND35 appeared adult-like learning during the training trials in MWM ([@B53]). In this study, the anxiety-like behaviors and the cognitive functions were evaluated at PND23 (14-days post-HI) and PND35 (28-days post-HI), respectively.

Open Field Test {#S2.SS3}
---------------

The exploratory and anxiety-like behaviors of animals were assessed at 14 days post-HI in an open field test as described previously ([@B28]). Each mouse was placed in the corner of the box and allowed 5 min of exploration. The activities of crossings, rearings, and grooming, and the time in center were recorded for each minute of the test.

Morris Water Maze (MWM) {#S2.SS4}
-----------------------

The spatial reference memory at 28 days post-HI was assessed using the MWM test as previously described ([@B28]). On training trials, the time required to locate and climb onto the platform (escape latency) was measured for 5 consecutive days (four trials/day). On probe trial (day 6), the time to reach the original platform in the target zone and total time traveled in the target zone were recorded.

Evaluation of Neuropathological Injury {#S2.SS5}
--------------------------------------

For histological endpoint determinations, brains were harvested, fixed in 4% formaldehyde, and then sliced into 5 μm coronal sections in the region containing the infarct lesion (between −1.60 and −2.00 mm from bregma). Slices were then analyzed using Nissl staining, TUNEL staining, and immunofluorescence or immunohistochemical imaging ([@B28]). Analyses of the images were performed using the Image-Pro Plus 6.0 software by an investigator blinded as to experimental group assignments. The number of active caspase-3/NeuN double positive cells, Nrf-2 positive cells, and TUNEL-positive cells were counted within randomly selected peri-infarct areas (within 300 μm to the infarct). The number of Iba-1 positive cells was measured in the core region of the infarct at × 20 magnifications. Activated microglia scores were assigned as previously described ([Table 2](#T2){ref-type="table"}) ([@B48]).

###### 

Semi-quantitative scores for Iba-1 staining.

  Score   Microglial appearance
  ------- ----------------------------------------------------------
  0       No activation
  1       Foci of non-ramified active microglia
  2       \<50% coverage of active microglia
  3       Widespread active and predominantly phagocytic microglia
  4       Total phagocytic activation

Nissl Staining {#S2.SS6}
--------------

For Nissl quantification of brain atrophy, brain sections from each group described above (*N* = 4 mice/group) were incubated with 0.5% cresyl violet acetate for 20 min to compare hemispheric atrophy among the groups. The hemispheric lesion volume was calculated using the following formula:
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Infarct Ratio Measurement {#S2.SS7}
-------------------------

After 3 days post-HI, mice were sacrificed and transcardially perfused with PBS to remove intravascular blood. The brain was harvested and divided them into four coronal sections. Each section was incubated within 2% of 2, 3, 5-TTC monohydrate at 37°C for 20 min. The software, Image-Pro Plus 6.0 was used for the summation of the volume of each section. The infarct ratio was calculated using the following formula:
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Transmission Electron Microscopy (TEM) {#S2.SS8}
--------------------------------------

The preparation method for transmission electron microscopy (TEM) analysis was similar to that described previously ([@B28]). The cortices from the ipsilateral hemisphere were fixed in 2.5% glutaraldehyde for 2 h, washed with PBS, fixed in 1% osmium tetroxide for 2 h, dehydrated in a graded series of ethanol, embedded in epoxy resin. Ultrathin (50 nm thickness) sections were obtained by Ultra microtome (EM UC 7, Leica, Germany), stained with uranyl acetate. The sections were photographed using Hitachi H-7500 TEM. In the present study, asymmetric synapses were examined for synaptic measurement ([@B55]). Asymmetric synapses exhibit the following characteristics: (1) typical asymmetric interface, i.e., the thickness of postsynaptic membrane is much bigger than that of presynaptic membrane; (2) PSD in the postsynaptic membrane; (3) round and clear synaptic vesicles. Six images per animal (20,000×) were used to observe the number of synapses (*n* = 4 each group). The number of synapses was expressed as the average of all the synapses in each photo taken at 20,000×. The synaptic cleft and the thickness of PSD was described in each photo taken at 20,000×.

Western Blot Analysis {#S2.SS9}
---------------------

Animals were decapitated after anesthesia at 3, 14, and 28 days after HI insult. Isolated cortices from the right hemisphere were separated and frozen at −80°C. Frozen tissue was cut into small pieces and homogenized in ice-cold RIPA lysis buffer containing 1% PMSF and 0.05% (vol/vol) PhosSTOP phosphatase inhibitor. After centrifugation at 10,000 × *g* for at 4°C 10 min, the supernatant was collected, and then measured the protein concentration using a BCA protein assay kit. The tissue samples were mixed with 5 × loading buffer and boiled for 10 min at 100°C. The proteins were loaded onto a 4--20% gradient polyacrylamide gel, electrophoretically transferred to polyvinylidene difluoride membrane, and probed with the following primary antibodies (all antibody information is presented in [Table 1](#T1){ref-type="table"}).

DHE Analysis {#S2.SS10}
------------

For determinations of ROS production in brain sections, brains were harvested, fixed in 4% formaldehyde, and then sliced into 12 μm coronal sections in the region containing the infarct lesion (between −1.60 and −2.00 mm from bregma). The frozen coronal sections from the ipsilateral hemisphere were stained with dihydroethiduim (DHE) as previously described ([@B52]). Briefly, coronal sections were stained with 10 μM DHE for 30 min. After rinsing and mounting, the fluorescence images were captured with use of fluorescent microscopy (BX51; Olympus, Tokyo, Japan). The DHE-staining results were pixilated and quantified using the Image-pro plus image analysis system.

Flow Cytometric Analysis {#S2.SS11}
------------------------

Single cells were prepared as previously described ([@B21]; [@B56]) with minor modifications. Briefly, the ipsilateral cortex was quickly removed and immersed into PBS containing 0.2% BSA (w/v) on ice. The cortices of each group were gently ground on the 70 μm cell strainer at 4°C. Then, homogenates were filtered by passing through a 70 μm cell strainer. The cell suspension was centrifuged at 400 × g for 10 min to obtain precipitation, and the cells were re-suspended with 40% Percoll solution, followed by the addition of 75% Percoll solution at the bottom, and centrifuged at 500 × g for 20 min. Cells were collected from two density gradient interfaces and incubated by these antibodies for 30 min at 4°C: anti-mouse CD45-APC (10311, Biolegend) or anti-mouse CD11b-FITC (101206, Biolegend), to evaluate the populations of infiltrating monocytes/neutrophils (CD11b^+^/CD45^high^ cells). Flow cytometric analysis was performed with use of FACS flow cytometer C6 (BD Biosciences). CD11b^+^ cell populations were further gated for CD45 expression and divided into a low (microglia) and high population (infiltrating monocytes/neutrophils).

Statistical Analysis {#S2.SS12}
--------------------

Data were analyzed by the SPSS software program. All values presented are expressed as the mean ± standard deviation. Data from the training trials in the MWM were averaged for each mouse (total data/total number of trials per day). Daily performance scores in the MWM tests were evaluated with use of a repeated-measures two-way analysis of variance (ANOVA) with "days" as the within-subject factor and "groups" as the between-subject factor. Daily scores of different groups in MWM tests were compared using one-way ANOVA, following by *post hoc* Bonferroni corrections for multiple comparisons. Correlation analysis between Bax/Bcl-2 ratio and TUNEL counts, between Syn/PSD protein 95 staining and escape latencies from day 1 to day 6 in MWM test was performed with Pearson correlation test. Unless otherwise indicated, other data were analyzed using the one-way ANOVA, and *post hoc* analysis between groups was performed using the Bonferroni corrections for multiple comparisons in this study. A *p*-value \< 0.05 was required for results to be considered statistically significant.

Results {#S3}
=======

PUR Prevents HI-Induced Brain Injury {#S3.SS1}
------------------------------------

In the preliminary pilot study, we tested the effects of PUR at 1, 5, and 10 mg/kg upon infarct volumes and edema. PUR treatment at 5 and 10 mg/kg reduced infarct volumes (*p* \< 0.05, *p* \< 0.001, respectively), PUR treatment at 10 mg/kg reduced edema (*p* \< 0.001), compared with those in the HI group at 72 h post-HI. From these studies, we established that the 10 mg/kg dose exerted remarkable beneficial effects in the absence of any toxicity (data not shown) and therefore we chose this dose for the subsequent experimental studies.

As shown in [Figure 1A](#F1){ref-type="fig"}, HI insult led to a remarkable edematous condition and significantly increased the water content within the ipsilateral side at 72 h following HI. PUR treatment markedly reduced this HI-induced brain edema (*p* \< 0.001) as compared with vehicle-HI group.

![Effects of PUR on HI-induced brain injury at 72 h post-HI insult. **(A)** Representative images of brain sections from each group. Arrows indicate edematous change in morphology within the ipsilateral hemisphere. Quantification of brain water content within ipsilateral and contralateral brain hemispheres was measured (*N* = 6/group). **(B)** Representative TTC stained brain sections of each group. Coronal sections were processed with 2% TTC staining for 20 min, and infract volume quantification was determined: infarct volume = (contralateral hemispheric volume -- ipsilateral non-infarcted volume)/contralateral hemispheric volume. Quantitative analysis of lesion volume of each group (*N* = 6/group). **(C)** Representative Nissl staining of coronal sections of each group. Brain sections from each group (four sections/mouse) were incubated with 0.5% cresyl violet acetate for 20 min. Nissl staining measurements were analyzed with use of Image-Pro Plus 6.0 software. Scale bar = 2 cm. **(D)** Quantification of amount of tissue loss of each group. Values represent the mean ± SD with *N* = 6/group. Values represent the mean ± SD, \**p* \< 0.05, \*\*\**p* \< 0.001 according to ANOVA with Bonferroni correction.](fphar-11-00204-g001){#F1}

Results from TTC and Nissl stainings showed that the significant increases in brain infarction areas (*p* \< 0.001, [Figure 1B](#F1){ref-type="fig"}) and tissue loss (*p* \< 0.001, [Figures 1C,D](#F1){ref-type="fig"}) were present within the ipsilateral side at 72 h post-HI. Treatment with PUR, blocked HI-induced brain infarction (*p* \< 0.001, [Figure 1B](#F1){ref-type="fig"}) and tissue loss (*p* \< 0.001, [Figures 1C,D](#F1){ref-type="fig"}).

Next, we used TEM to confirm neural damage. The neurons in Sham group appeared normal, while neurons in the ipsilateral side of HI group exhibited severely ultrastructural damage at 72 h post-insult. The cytoplasm vacuolization, irregular nuclei, and discontinuous cell membrane were found in some areas. Some vacuoles were shown in mitochondria, and ER exhibited remarkable swelling. However, post-treatment with PUR following HI insult relieved this morphological damage. The ultra-microstructure of neuron in HI + PUR group was similar to those of Sham group ([Supplementary Figure S2](#FS2){ref-type="supplementary-material"}).

These beneficial effects of PUR on edema, infarct volume, and morphological damage were significantly blocked when mice were pretreated with Cyc combined with PUR. Brain injury in animals pretreated with Cyc alone was not more severe than that in the HI group ([Figure 1](#F1){ref-type="fig"}).

PUR Decreases TUNEL-Positive Cells and Apoptotic Markers {#S3.SS2}
--------------------------------------------------------

Results from TUNEL staining revealed that PUR treatment significantly reduced cell apoptosis following HI injury (*p* \< 0.01, [Supplementary Figure S3](#FS3){ref-type="supplementary-material"}). HI insult remarkably increased the Bax/Bcl-2 ratio at protein level, while PUR treatment prevented these effects ([Figure 2A](#F2){ref-type="fig"}). Cyc administration reversed the effect of PUR on apoptosis and Bax/Bcl-2 ratio after HI injury ([Figure 2](#F2){ref-type="fig"}). Pearson correlational analysis revealed that Bax/Bcl-2 ratio in protein were positively associated with TUNEL counts following HI insult in mice (*r* = 0.895^∗∗^, *p* \< 0.001).

![PUR alleviates HI-induced apoptosis at 72 h post-HI insult. **(A)** Levels of Bax and Bcl-2 within the ipsilateral cortex were measured with use of western blotting. Quantification of protein levels of Bax and Bcl-2 were determined with use of Image-Pro Plus 6⋅0 (*N* = 4/group). **(B)** Double immunofluorescent staining of active caspase-3 (red) and NeuN (green) within the ipsilateral cortex. Scale bar = 50 μm. **(C)** Quantification of active caspase-3/NeuN-positive cells (*N* = 4/group). Six images (20×) were captured randomly for each section per animal. **(D)** Immunoblotting analysis of active caspase-3, caspase-3 within the ipsilateral cortex. **(E)** Image-Pro Plus 6.0 was used to quantify protein levels of caspase-3 and active caspase-3. Results are expressed as the ratio of active caspase-3/caspase-3 (*N* = 4/group). Values represent the mean ± SD, \**p* \< 0.05, \*\**p* \< 0.01, \*\*\**p* \< 0.001 according to ANOVA with Bonferroni correction.](fphar-11-00204-g002){#F2}

Active caspase-3/NeuN double staining showed that the number of apoptotic neurons in the HI group was markedly increased as compared with that in the Sham group (*p* \< 0.001), while PUR treatment significantly decreased the number of active caspase-3/NeuN positive-neurons as compared to vehicle-treated HI mice (*p* \< 0.01, [Figures 2B,C](#F2){ref-type="fig"}). Following HI insult, levels of active caspase-3 in the ipsilateral cortex were increased compared with that of the Sham group (*p* \< 0.001), while active caspase-3 was decreased in the PUR treatment group (*p* \< 0.001) as determined using Western blotting analysis ([Figure 2D](#F2){ref-type="fig"}). These beneficial effects of PUR in decreasing HI-induced caspase-3 activation in mice were blocked by Cyc administration ([Figure 2](#F2){ref-type="fig"}), suggesting that PUR suppressed HI-induced caspase-dependent apoptosis.

The Role of PUR on the Shh Signaling Pathway in HI Injury {#S3.SS3}
---------------------------------------------------------

Hypoxic-ischemic exposure produced a decrease in the protein expressions of Shh (*p* \< 0.01), Ptch (*p* \< 0.05), and Gli-1 (*p* \< 0.01). PUR treatment reversed HI-downregualted Shh (*p* \< 0.05), Ptch (*p* \< 0.05), and Gli-1 (*p* \< 0.05) expressions ([Figure 3](#F3){ref-type="fig"}). These effects of PUR on the Shh pathway following HI exposure were partially blocked by Cyc pre-treatment ([Figure 3](#F3){ref-type="fig"}).

![Effects of PUR administration on the Shh pathway. Quantification of Shh, Gli-1, and Ptch was determined with use of western blot as performed at 72 h post-HI. Quantification of protein levels of Shh, Gli-1, and Ptch was determined with use of Image-Pro Plus 6.0 (*N* = 4/group). Values represent the mean ± SD, \**p* \< 0.05, \*\**p* \< 0.01 according to ANOVA with Bonferroni correction.](fphar-11-00204-g003){#F3}

PUR Suppressed Neuro-Inflammation Following HI Insult {#S3.SS4}
-----------------------------------------------------

Increased Iba-1 labeling cells were observed in the core region of the infarct (*p* \< 0.001) following HI, with most of the microglia exhibiting a rounded amoeboid-like appearance. However, PUR treatment decreased HI-increased Iba-1 labeling cells (*p* \< 0.001) ([Figures 4A,C](#F4){ref-type="fig"}), with most of the microglia exhibiting a resting phenotype based on microglial activation score (*p* \< 0.001) ([Figure 4D](#F4){ref-type="fig"}).

![PUR suppressed microglial activation and inflammatory gene expression. **(A)** Expression of Iba-1 within the ipsilateral cortex was examined at 3 days after HI with use of immunohistochemical staining. Green arrow---resting microglia (ramified microglia) and red arrowhead---activated microglia (amoeboid shape). **(B)** Representative flow cytometric lots of CD11b^+^/CD45^high^ cells within ipsilateral cortex. The infliting monocytes/neutrophils in the upper right quadrant (blue rectangle) (CD11b^+^/CD45^high^). **(C)** Quantification of Iba-1^+^ cell numbers in infarct core regions. *N* = 4/group. **(D)** Quantitative assessment of PUR effect on microglial activation score. *N* = 4/group. **(E)** Quantification of CD11b^+^/CD45^high^ cell numbers in ipsilateral cortex. *N* = 4/group. Values represent the mean ± SD, \*\**p* \< 0.01, \*\*\**p* \< 0.001 according to ANOVA with Bonferroni correction.](fphar-11-00204-g004){#F4}

In the HI brain, there is also a considerable contribution of infiltrating peripheral immune cells to the brain after injury ([@B20]). Next, we investigated the effect of PUR administration on infiltrating monocytes/neutrophils (CD11b^+^/CD45^high^ cells). The result showed that HI exposure remarkedly increased the number of infiltrating monocytes/neutrophils (CD11b^+^/CD45^high^ cells) (*p* \< 0.001) within the ipsilateral cortex at 72 h following injury, while PUR administration significantly attenuated these increases (*p* \< 0.001) ([Figures 4B,E](#F4){ref-type="fig"}).

Effects of PUR on Oxidative Defenses After HI Insult {#S3.SS5}
----------------------------------------------------

The ROS content was substantially increased in the ipsilateral cortex at 72 h post-HI injury with DHE staining, whereas PUR treatment suppressed this HI-induced ROS production (*p* \< 0.01, [Figures 5A,C](#F5){ref-type="fig"}). Western blot analysis showed that Nrf-2 protein in the ipsilateral cortex was slightly downregulated following HI injury. PUR treatment resulted in significantly higher levels of Nrf-2 expression than that observed within the vehicle-HI group (*p* \< 0.05, [Figure 5E](#F5){ref-type="fig"}). These results were corroborated by the data obtained from immunohistochemical analysis ([Figures 5B,D](#F5){ref-type="fig"}). Pre-treatment with Cyc decreased Nrf-2 levels as compared with those observed in the HI + PUR group ([Figures 5B,E](#F5){ref-type="fig"}).

![Effect of PUR on ROS level and Nrf2 expression at 72 h post-HI insult. **(A)** The ipsilateral cortex was processed for ROS analysis. Frozen cortex sections were stained for 30 min with DHE to obtain quantitative data of relative fluorescence. Scale bar = 50 μm. **(B)** Immunohistochemical staining of Nrf2 expression within the ipsilateral cortex. Scale bar = 50 μm. **(C)** Quantification of ROS was determined with use of Image-Pro Plus image analysis system. Values are expressed relative to those of the Sham group (*N* = 4/group). **(D)** Quantitative analysis of the number of Nrf2-positive cells (stained in brown). Values are expressed relative to those of the Sham group (*N* = 4/group). Six images (20×) were captured randomly for each section per animal. **(E)** Western blotting was used to measure levels of Nrf-2 within the ipsilateral cortex. Quantification of protein levels of Nrf-2, as determined with use of Image-Pro Plus 6⋅0 (*N* = 4/group). Values represent the mean ± SD, \**p* \< 0.05, \*\**p* \< 0.01, \*\*\**p* \< 0.001 according to ANOVA with Bonferroni correction.](fphar-11-00204-g005){#F5}

Effects of PUR on Synaptic Remodeling at 3, 14, and 28 Days After HI {#S3.SS6}
--------------------------------------------------------------------

As observed using TEM, synaptic density was increased at PND21 and PND35 compared with that at PND10 in each group ([Figure 6](#F6){ref-type="fig"}). HI exposure reduced the numeric synaptic densities at 3, 14, and 28 days post-HI insult (*p* \< 0.001, *p* \< 0.001, *p* \< 0.01, respectively; [Figure 6](#F6){ref-type="fig"}). Synaptic clefts were widened in response to HI. A few synapses were completely destroyed by HI insult. However, in response to PUR treatment, no significant differences were identified in synaptic ultra-structures in the HI as compared with that of the Sham group ([Figure 6](#F6){ref-type="fig"}).

![Effects of PUR on synaptic damage post-HI insult. Representative electron micrographs images indicating \*: presynaptic vesicles, red arrow: postsynaptic partners, green arrow: few vesicles but no postsynaptic partner, red arrowhead: destroyed synapses, green arrowhead: widened synaptic clefts. Quantification of the number of synapses at 3, 14, and 28 days post-HI insult (*N* = 4/group). The number of synapses was expressed as the average of all synapses present in each photo taken at 20,000×.](fphar-11-00204-g006){#F6}

Within the ipsilateral cortex, expression levels of Syn and PSD95 proteins were substantially downregulated at 3, 14, and 28 days after HI insult ([Supplementary Figure S4](#FS4){ref-type="supplementary-material"}). PUR treatment significantly increased the expression of Syn and PSD95 at 3, 14, and 28 days after HI insult, compared with HI group ([Figure 7](#F7){ref-type="fig"}). Cyc combined with PUR markedly inhibited these beneficial effects of PUR on Syn and PSD95 expression ([Figure 7](#F7){ref-type="fig"}).

![Effects of PUR on synaptophysin (Syn) and PSD95 expression post-HI insult. Immunoblotting analysis of Syn and PSD95 within the ipsilateral cortex. Quantification of expression levels of Syn and PSD95 as determined with use of Image-Pro Plus 6.0 (*N* = 4/group). Values represent the mean ± SD, \**p* \< 0.05, \*\**p* \< 0.01, \*\*\**p* \< 0.001 according to ANOVA with Bonferroni correction.](fphar-11-00204-g007){#F7}

PUR Ameliorated Brain Atrophy and Locomotor Activity 2 Weeks After HI {#S3.SS7}
---------------------------------------------------------------------

Substantial brain atrophy and asymmetry were found 14 days after HI exposure. Treatment with PUR partially alleviated this damage ([Figure 8A](#F8){ref-type="fig"}). At the same time, HI insult resulted in a large area of tissue loss within the ipsilateral cortex, PUR treatment was able to prevent HI-induced tissue loss (*p* \< 0.01, [Supplementary Figure S5](#FS5){ref-type="supplementary-material"}) as indicated by Nissl staining.

![Effects of PUR on brain atrophy and behavioral changes following HI insult. **(A)** Representative morphology of the brain of each group at 14 days post-HI. Arrows indicate atrophy within the ipsilateral hemisphere. **(B)** Locomotion was measured within an open field test (*N* = 8/group). Each mouse was placed in the corner of the box and allowed 5 min of exploration. The following behaviors were recorded for each mouse: number of squares crossed (crossing), frequency of standing on hind limbs (rearing), number of times the animal was observed grooming their face, licking/cleaning and scratching various parts of the body (grooming), and amount of time traveled in the center area of the maze. **(C)** During each acquisition trial in the MWM test, all the animals were allowed 60 s per trial to locate the escape platform, which was submerged 2 cm below the water surface and located in the center of quadrant III. The time required to locate and climb onto the platform (escape latency) was measured for 5 consecutive days (four trials/day). **(D)** On probe trial (day 6), the platform was removed from the tank. Animals were placed in quadrant IV and their swimming path was traced for the following 60 s of the test. The time to reach the original platform in the target zone and total time traveled in the target zone were recorded. **(E)** Display of tracks of all groups on day 6 (*N* = 8/group). Values represent the mean ± SD, \**p* \< 0.05, \*\**p* \< 0.01, \*\*\**p* \< 0.001 daily scores were compared using ANOVA with Bonferroni correction.](fphar-11-00204-g008){#F8}

With regard to anxiety-like behaviors, an overall statistically significant difference among the groups was obtained for the number of crossings (*p* \< 0.001) and rearings (*p* \< 0.01), but grooming (*p* \> 0.05) and time in the center (*p* \> 0.05) failed to show any overall significant differences among the groups. *Post hoc* analysis revealed that exposure to HI substantially increased crossing (*p* \< 0.001) and rearing (*p* \< 0.01) scores, while treatment with PUR showed significantly lowered crossing (*p* \< 0.01) and rearing (*p* \< 0.05) scores as compared with that of the HI group. These beneficial effects of PUR on brain damage and anxiety-like behaviors at PND 21 after HI were partially reversed by Cyc pre-treatment ([Figure 8B](#F8){ref-type="fig"}).

Effects of PUR on MWM Test Performance After HI {#S3.SS8}
-----------------------------------------------

Many studies demonstrated that HI injured animals showed deficits on a long-term reference memory in MWM test ([@B6]). In the study, mean latencies declined progressively from training days 1 to day 5 in each group \[*F*(4,35) = 11.634, *p* \< 0.001\] and no significant interaction between training days and groups was present \[*F*(4,35 = 1.236, *p* \> 0.05\] by repeated measures ANOVA. These data revealed that all mice showed the same improvements in spatial learning and memory over time, regardless of previous treatment. In the initial 3 days of testing, no statistically significant differences in latencies were obtained among the groups (*p* \> 0.05). However, on day 4 and 5, HI animals spent significantly longer time to locate the platform as compared with the Sham group (*p* \< 0.05, *p* \< 0.01, respectively, [Figure 8C](#F8){ref-type="fig"}). In response to PUR treatment, a progressive reduction in escape latencies was observed with differences being statistically significant on day 5 (*p* \< 0.05, [Figure 8C](#F8){ref-type="fig"}).

In the probe trial, all mice were swimming mostly in quadrant III, where the hidden platform was originally located. The HI group spent significantly less time in quadrant III when compared to the Sham group (*p* \< 0.05, [Figures 8D,E](#F8){ref-type="fig"}). However, mice treated with PUR spent significantly increased amounts of time in the target zone as compared with that of the HI group (*p* \< 0.05, [Figures 8D,E](#F8){ref-type="fig"}). Significantly decreased escape latencies were observed in the PUR in comparison to that of the HI group (*p* \< 0.05, [Figures 8D,E](#F8){ref-type="fig"}). Pre-treatment with Cyc significantly blocked these effects of PUR upon MWM test results. Pearson correlational analysis showed that Syn/PSD95 staining was not associated with escape latencies from day 1 to day 6 in MWM test ([Table 3](#T3){ref-type="table"}).

###### 

Pearson correlational analysis between Syn/PSD95 labeling with escape latencies from day1 to day 6 in MWM test.

                       Syn/PSD95 labeling   Escape latencies in day 1   Escape latencies in day 2   Escape latencies in day 3   Escape latencies in day 4   Escape latencies in day 5   Escape latencies in day 6
  -------------------- -------------------- --------------------------- --------------------------- --------------------------- --------------------------- --------------------------- ---------------------------
  Syn/PSD95 labeling   *r*^2^ = 1           *r*^2^ = −0.213             *r*^2^ = −0.215             *r*^2^ = 0.209              *r*^2^ = 0.035              *r*^2^ = −0.242             *r*^2^ = −0.442
                                            *p* = 0.368                 *p* = 0.363                 *p* = 0.376                 *p* = 0.882                 *p* = 0.304                 *p* = 0.051

Discussion {#S4}
==========

In the present study, we demonstrate that treatment with PUR following HI insult protected against acute brain injury and long-term memory and learning deficits in neonatal mice. Some of these beneficial effects of PUR could be attributed to the attenuation of HI-induced synaptic impairments, the reduction in neuro-inflammation and ROS levels, as well as the involvement of the Shh signaling pathway.

Neuronal Cell Death and Neuro-Inflammation Were Attenuated Following PUR Treatment {#S4.SS1}
----------------------------------------------------------------------------------

The Shh pathway plays a key role in tissue repair after ischemic damage, which has been demonstrated within the heart ([@B26]), brain ([@B13]), and skeletal muscle ([@B38]). Shh signaling triggered by resveratrol reduced infarct volume and reversed neurological deficits after stroke ([@B57]). Additionally, Shh pathway activation by Shh agonist improved behavioral deficits resulting from focal cortical ischemic injury ([@B24]). Recently, PUR was found to participate in neuroprotective effects against ischemic injury, which were reported to be independent of the Shh signaling pathway ([@B12]). Previous work within our laboratory has indicated that PUR provided neuroprotection against subarachnoid hemorrhage-induced injury ([@B22]). However, only limited information currently exists in support of PUR neuroprotection and its mechanisms, which may involve anti-inflammatory, anti-apoptotic, and/or pro-angiogenic processes after ischemic insult ([@B12]; [@B11]). In addition, immediate microglial activation occurs following HI and mediates brain injury ([@B19]; [@B42]). Activated microglia mainly contributes to neuro-inflammation and releases inflammatory mediators including tumor necrosis factor-α and interleukin-1β, leading to neuronal dead and excitotoxic injury ([@B31]). Pharmacologic inhibition of microglial activation suppresses HI-induced neuronal apoptosis ([@B5]; [@B27]). In this study, PUR treatment markedly suppressed microglia activation and inflammatory cytokines levels, and reduced infarct size and neuronal apoptosis after HI. Taken together, blocking microglial activation may contribute to the neuroprotective effects of PUR in immature brain in mice following HI.

The capacity for PUR to exert antioxidant effects in HI, as revealed by significantly decreasing HI-induced ROS levels, was consistent with a previous study ([@B22]). A number of antioxidants, including allopurinol, erythropoietin, resveratrol, and omega-3 fatty acids, have been shown to exhibit neuroprotective properties in different animal models of perinatal HI brain injury ([@B34]; [@B4]; [@B39]). In this study, PUR minimized oxidative stress associated with HI insult, as indicated with increased Nrf-2 expression levels. Nrf-2 is an redox-sensitive transcription factor that mainly mediates the expression of antioxidant enzymes, including heme oxygenase-1 and NAD(P)H:quinone oxidoreductase 1, to defend against oxidative damage and other stressful events ([@B1]). Nrf-2 activation in response to increased ROS can reduce ischemic brain injury ([@B41]; [@B58]). Moreover, upregulation of Nrf-2 in neurons can protect against oxidative and excitotoxic insults ([@B47]). These findings, along with our current results, suggest that the protective effects of PUR against oxidative stress, in part, occur via an increase in antioxidant expression. Moreover, an anti-apoptotic role of PUR was also present following HI injury. Since PUR or Shh agonists protect cortical neurons from apoptosis via a reduction of oxidative stress ([@B14]; [@B35]), we speculated that the anti-apoptotic effects of PUR observed following HI injury, in part, may result from a reduction in oxidative stress through Nrf-2 activation. Additional work will be required to investigate the mechanisms through which PUR activates Nrf-2 in HI brain injury.

PUR Attenuated Synaptic Damage Following HI Injury {#S4.SS2}
--------------------------------------------------

During their initial developmental stages, animals subjected to HI injury show delayed neurite outgrowth and synaptogenesis, resulting in subsequent long-term memory impairments ([@B9]; [@B17]). In rodents, cortical synaptic density is initially low in the newborn, but rapidly increases from PND10 until PND30, when equivalent levels to that observed in adults are present ([@B40]). Consistent with this previous study, we found that synaptic density increased from PND10 to PND21 and PND35 in each group. However, in mice subjected to HI, synaptic density at PND21 and PND35 reduced as compared with the Sham group. In addition, these reductions in synaptic densities were associated with decreased levels of synaptic proteins.

Synaptic proteins are directly involved in synaptic plasticity and related to cognitive function. A number of postsynaptic proteins including PSD95, PSD93, and synapse-associated protein 102 have been shown to be downregulated following early HI insult in neonatal mice ([@B42]). In addition, changes in synaptic morphology were associated with impaired recognition memory post-HI in neonatal rats ([@B33]). In the present study, reduced Syn and PSD95 expression levels were found in the cortex during early and advanced stages of development following HI insult. However, reduced Syn/PSD95 expression was not associated with behavioral abnormality in MWM test. Thus, the long-term memory impairments resulting from HI insult could not be attributed to the changes in Syn and PSD95 expression within the cortex.

Shh and its signaling receptor components are present in both presynaptic and postsynaptic terminals of the developing and adult CNS, suggesting that this pathway contributes to the synaptic plasticity of differentiated neurons ([@B36], [@B37]). It was reported that Shh agonist was able to improve learning and memory deficits in a Down syndrome mouse model ([@B15]). Recent findings also found that stimulation of Shh release from neurons and astrocytes by bone marrow stromal cells could promote neurite outgrowth, synaptogenesis, and myelination ([@B16]). Our study showed that PUR treatment alleviated the synaptic loss and upregulated synaptic proteins expression following HI injury, which was associated with the involvement of the Shh pathway.

PUR Restored Levels of Shh Signaling After HI {#S4.SS3}
---------------------------------------------

The endogenous Shh pathway participates in regenerative responses after damage to diverse brain regions, including the cerebral cortex and corpus callosum ([@B32]). For example, a maximal activation of the Shh pathway was observed at 3 days after cortical freeze injury followed by a return to baseline levels at 14 days ([@B3]). Shh protein levels in the cortex were increased at 1--5 days after injury following a cortical stab wound ([@B46]). In addition, the endogenous Shh pathway in the cortex and hippocampus was reported to be upregulated in response to stroke and ischemic insult ([@B43]; [@B12]). However, Shh expression in the cortex was downregulated in the early stages after experimental subarachnoid hemorrhage ([@B59]; [@B22]). In the present study, the expression of Shh signaling including Shh and Ptch within brain was reduced following HI insult. PUR treatment produced an increased expression of Shh signaling 3 days post-HI, associated with reduced acute brain injury and improved long-term memory and learning deficits following HI. The significance of Shh signaling pathway was substantiated with the demonstration that Cyc treatment blocked these beneficial effects of PUR. Taken together, these data provided strong evidence indicating that PUR plays a protective role in HI-induced injury through activation of the Shh signaling pathway.

One limitation in this study was that ROS levels were measured using the DHE probes. In the presence of the superoxide anion, DHE is rapidly oxidized to oxyethidium, which binds DNA and emits light to monitor ROS activity ([@B23]). However, DHE is also easily oxidized by heme peroxidases. In the ischemic brain, heme peroxidase is elevated and released, which leads to an increase in ROS formation when monitored by ROS-sensitive fluorescent probes ([@B25]; [@B29]). To complement this, there are ongoing attempts to develop a new generation of ROS probes to measure ROS activity *in vivo*.

Conclusion {#S5}
==========

In summary, PUR, a Shh pathway agonist, exerts protection against HI-induced injury in neonatal mice, as evidenced by its beneficial effects upon multiple parameters including acute brain injury, neuro-inflammtion, long-term memory deficits, and impaired synaptic function. Accordingly, PUR may serve as a promising new therapeutic drug candidate for HI injury, which can specifically and sensitively target the Shh signaling pathway to exert its beneficial effects.

Data Availability Statement {#S6}
===========================

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation, to any qualified researcher.

Ethics Statement {#S7}
================

The animal study was reviewed and approved by the Animal Ethical and Welfare Committee of Shandong University.

Author Contributions {#S8}
====================

ZW made substantial contributions to study design, data interpretation, writing and revising of the manuscript, and final revision of the manuscript. DL made substantial contributions to rewriting and revising final manuscript, reading and editing proof, and performed data analysis and transmission electron microscopy. XB performed animal model, Western blot analysis, ROS content, and evaluation of neuropathological injury. WM performed Western blot analysis. DX, XC, HY, and JQ performed behavioral testing. HK, SY, and WC revised the manuscript. All authors read and approved the final draft of this manuscript.

Conflict of Interest {#conf1}
====================

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

**Funding.** Research funding support for this work was from the National Natural Science Foundation of China (Nos. 81671213 and 81873768 to ZW), the Key Research and Development Foundation of Shandong Province (No. 2017GSF218091 to ZW), and the National Key Research and Development Program of China (No. 2017YFC0820203 to DL), the National Key Project of Chronic Non-Communicable Disease of China (No. 2016YFC1300403 to WC), National Natural Science Foundation of China (No. 81770436 to WC).

We gratefully acknowledge Liyan Wang and Xianghong Zhang for their assistance with transmission electron microscopy.

Supplementary Material {#S11}
======================

The Supplementary Material for this article can be found online at: <https://www.frontiersin.org/articles/10.3389/fphar.2020.00204/full#supplementary-material>

###### 

Schema for PUR treatment schedule, behavioral experiments, and tissue preparation. The pups on postnatal day 7 underwent right common carotid artery ligation, and hypoxia was induced (humidified 8% O~2~+92% N2 for 1.5 h). PUR or Cyc solutions were administered via intraperitoneal injection at 1, 2, and 3 days after HI insult. In the HI+PUR+Cyc group, Cyc was administered 30 min before PUR injection. The Sham and HI groups were treated with the same volume of the vehicle relative to body weight. Cyc, cyclopamine; HI, hypoxia-ischemia; ip, intraperitoneally; P, postnatal day; PUR, Purmorphamine; MWM, Morris water maze.

###### 

Click here for additional data file.

###### 

Effects of PUR on HI-induced neuronal damage. The representative transmission electron microscopy image of ipsilateral cortex. N = 4/group. Arrow indicates dissolved membrane. Asterisk points to swelling and vacuolization of mitochondria. Red arrowhead points to severe cytoplasmic edema. Scale bar = 2 μm. N, Nucleus; M, mitochondria; ER, rough endoplasmic reticulum.
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Click here for additional data file.

###### 

Effects of PUR on HI-induced neuronal apoptosis. Three days following HI insult, sections form each group were subjected to TUNEL assay (green), counterstained with Dapi (blue). Scale bar = 50 μm. The percentage of TUNEL-positive cells was expressed as the number of positively stained apoptotic cells/the total cells counted. N = 4/group. Values represent the mean ± SD, \*\**p* \< 0.01, \*\*\**p* \< 0.001, according to ANOVA with Bonferroni correction.
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Click here for additional data file.

###### 

The expression of Syn and PSD95 at 3, 14 and 28 days post-HI. The quantification of Syn and PSD95 within ipsilateral cortex was measured by Western blot at 3, 14, 28 days post HI. N = 3/group. Values represent the mean ± SD, \**p* \< 0.05, \*\**p* \< 0.01, according to ANOVA with Bonferroni correction.
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Click here for additional data file.

###### 

Effects of PUR administration on tissue loss at 14 days post-HI insult. Representative coronal sections of Nissl staining were obtained from different groups at 14 days after HI injury. Scale bar = 2000 μm. The quantification of tissue loss was determined with use of Image-Pro Plus 6⋅0. N = 6/group. Values represent the mean ± SD, \**p* \< 0.05, \*\**p* \< 0.01, \*\*\**p* \< 0.001, according to ANOVA with Bonferroni correction.

###### 

Click here for additional data file.

Cyc

:   cyclopamine

DAPI

:   4′,6-diamidino-2-phenylindole dihydrochloride

HI

:   hypoxic-ischemic

Iba-1

:   ionized calcium binding adaptor molecule-1

MWM

:   Morris water maze

Nrf-2

:   nuclear factor-E2-related factor-2

OGD

:   oxygen-glucose deprivation

PND

:   postnatal day

PSD

:   postsynaptic density protein

Ptch

:   patched

PUR

:   purmorphamine

ROS

:   reactive oxygen species

Shh

:   sonic hedgehog

Smo

:   Smoothened

Syn

:   synaptophysin

TTC

:   triphenyltetrazolium chloride
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